TY - JOUR AU - Dhamoon, M. S. AU - Sciacca, R. R. AU - Rundek, T. AU - Sacco, R. L. AU - Elkind, M. S. PY - 2006 DA - 2006// TI - Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study JO - Neurology. VL - 66 UR - https://doi.org/10.1212/01.wnl.0000201253.93811.f6 DO - 10.1212/01.wnl.0000201253.93811.f6 ID - Dhamoon2006 ER - TY - JOUR AU - Kernan, W. N. AU - Viscoli, C. M. AU - Furie, K. L. AU - Young, L. H. AU - Inzucchi, S. E. AU - Gorman, M. PY - 2016 DA - 2016// TI - Pioglitazone after ischemic stroke or transient ischemic attack JO - N Engl J Med VL - 374 UR - https://doi.org/10.1056/NEJMoa1506930 DO - 10.1056/NEJMoa1506930 ID - Kernan2016 ER - TY - JOUR AU - Mozaffarian, D. AU - Benjamin, E. J. AU - Go, A. S. AU - Arnett, D. K. AU - Blaha, M. J. AU - Cushman, M. PY - 2016 DA - 2016// TI - Heart disease and stroke statistics-2016 update: a report from the American Heart Association JO - Circulation VL - 133 UR - https://doi.org/10.1161/CIR.0000000000000350 DO - 10.1161/CIR.0000000000000350 ID - Mozaffarian2016 ER - TY - STD TI - WHO. The top 10 causes of death. 2016. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 4 May 2016. UR - http://www.who.int/mediacentre/factsheets/fs310/en/ ID - ref4 ER - TY - JOUR AU - Kessler, T. AU - Vilne, B. AU - Schunkert, H. PY - 2016 DA - 2016// TI - The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease JO - EMBO Mol Med. VL - 8 UR - https://doi.org/10.15252/emmm.201506174 DO - 10.15252/emmm.201506174 ID - Kessler2016 ER - TY - JOUR AU - Grundy, S. M. AU - Cleeman, J. I. AU - Daniels, S. R. AU - Donato, K. A. AU - Eckel, R. H. AU - Franklin, B. A. PY - 2005 DA - 2005// TI - Diagnosis and management of the metabolic syndrome an american heart association/national heart, lung, and blood institute scientific statement JO - Circulation VL - 112 UR - https://doi.org/10.1161/CIRCULATIONAHA.105.169404 DO - 10.1161/CIRCULATIONAHA.105.169404 ID - Grundy2005 ER - TY - JOUR AU - Wassink, A. M. J. AU - Der, G. r. a. a. f. Y. AU - Olijhoek, J. K. AU - Visseren, F. L. PY - 2008 DA - 2008// TI - Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm JO - Eur Heart J VL - 29 UR - https://doi.org/10.1093/eurheartj/ehm582 DO - 10.1093/eurheartj/ehm582 ID - Wassink2008 ER - TY - JOUR AU - Tanaka, R. AU - Yamashiro, K. AU - Okuma, Y. AU - Shimura, H. AU - Nakamura, S. AU - Ueno, Y. PY - 2015 DA - 2015// TI - Effects of pioglitazone for secondary stroke prevention in patients with impaired glucose tolerance and newly diagnosed diabetes: the J-SPIRIT study JO - J Atheroscler Thromb. VL - 22 UR - https://doi.org/10.5551/jat.30007 DO - 10.5551/jat.30007 ID - Tanaka2015 ER - TY - JOUR AU - Nissen, S. E. AU - Nicholls, S. J. AU - Wolski, K. AU - Nesto, R. AU - Kupfer, S. AU - Perez, A. PY - 2008 DA - 2008// TI - Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JO - JAMA VL - 299 UR - https://doi.org/10.1001/jama.299.13.1561 DO - 10.1001/jama.299.13.1561 ID - Nissen2008 ER - TY - JOUR AU - Dormandy, J. A. AU - Charbonnel, B. AU - Eckland, D. J. AU - Erdmann, E. AU - Massi-Benedetti, M. AU - Moules, I. K. PY - 2005 DA - 2005// TI - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial JO - Lancet VL - 366 UR - https://doi.org/10.1016/S0140-6736(05)67528-9 DO - 10.1016/S0140-6736(05)67528-9 ID - Dormandy2005 ER - TY - JOUR AU - Giannini, S. AU - Serio, M. AU - Galli, A. PY - 2004 DA - 2004// TI - Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity JO - J Endocrinol Invest VL - 27 UR - https://doi.org/10.1007/BF03347546 DO - 10.1007/BF03347546 ID - Giannini2004 ER - TY - JOUR AU - Ricote, M. AU - Li, A. C. AU - Willson, T. M. AU - Kelly, C. J. AU - Glass, C. K. PY - 1998 DA - 1998// TI - The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation JO - Nature VL - 391 UR - https://doi.org/10.1038/34178 DO - 10.1038/34178 ID - Ricote1998 ER - TY - JOUR AU - Corzo, C. AU - Griffin, P. R. PY - 2013 DA - 2013// TI - Targeting the peroxisome proliferator-activated receptor-γ to counter the inflammatory milieu in obesity JO - Diabetes Metab J. VL - 37 UR - https://doi.org/10.4093/dmj.2013.37.6.395 DO - 10.4093/dmj.2013.37.6.395 ID - Corzo2013 ER - TY - JOUR AU - Quinn, C. E. AU - Hamilton, P. K. AU - Lockhart, C. J. AU - McVeigh, G. E. PY - 2008 DA - 2008// TI - Thiazolidinediones: effects on insulin resistance and the cardiovascular system JO - Br J Pharmacol VL - 153 UR - https://doi.org/10.1038/sj.bjp.0707452 DO - 10.1038/sj.bjp.0707452 ID - Quinn2008 ER - TY - STD TI - Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, et al. Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes care. 2004;27:781–7. http://www.ncbi.nlm.nih.gov/pubmed/14988302. Accessed 9 Jul 2016. UR - http://www.ncbi.nlm.nih.gov/pubmed/14988302 ID - ref15 ER - TY - JOUR AU - Motoki, T. AU - Kurobe, H. AU - Hirata, Y. AU - Nakayama, T. AU - Kinoshita, H. AU - Rocco, K. A. PY - 2015 DA - 2015// TI - PPAR-γ agonist attenuates inflammation in aortic aneurysm patients JO - Gen Thorac Cardiovasc Surg. VL - 63 UR - https://doi.org/10.1007/s11748-015-0576-1 DO - 10.1007/s11748-015-0576-1 ID - Motoki2015 ER - TY - JOUR AU - Xu, W. AU - Bi, Y. AU - Sun, Z. AU - Li, J. AU - Guo, L. AU - Yang, T. PY - 2015 DA - 2015// TI - Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study) JO - J Intern Med VL - 277 UR - https://doi.org/10.1111/joim.12293 DO - 10.1111/joim.12293 ID - Xu2015 ER - TY - JOUR AU - Miyazaki, Y. AU - Mahankali, A. AU - Matsuda, M. AU - Mahankali, S. AU - Hardies, J. AU - Cusi, K. PY - 2002 DA - 2002// TI - Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients JO - J Clin Endocrinol Metab VL - 87 UR - https://doi.org/10.1210/jcem.87.6.8567 DO - 10.1210/jcem.87.6.8567 ID - Miyazaki2002 ER - TY - JOUR AU - Maeda, N. AU - Takahashi, M. AU - Funahashi, T. AU - Kihara, S. AU - Nishizawa, H. AU - Kishida, K. PY - 2001 DA - 2001// TI - PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein JO - Diabetes VL - 50 UR - https://doi.org/10.2337/diabetes.50.9.2094 DO - 10.2337/diabetes.50.9.2094 ID - Maeda2001 ER - TY - JOUR AU - DeFronzo, R. A. AU - Tripathy, D. AU - Schwenke, D. C. AU - Banerji, M. AU - Bray, G. A. AU - Buchanan, T. A. PY - 2011 DA - 2011// TI - Pioglitazone for diabetes prevention in impaired glucose tolerance JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1010949 DO - 10.1056/NEJMoa1010949 ID - DeFronzo2011 ER - TY - JOUR AU - Saremi, A. AU - Schwenke, D. C. AU - Buchanan, T. A. AU - Hodis, H. N. AU - Mack, W. J. AU - Banerji, M. PY - 2013 DA - 2013// TI - Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors JO - Arterioscler Thromb Vasc Biol VL - 33 UR - https://doi.org/10.1161/ATVBAHA.112.300346 DO - 10.1161/ATVBAHA.112.300346 ID - Saremi2013 ER - TY - JOUR AU - Martens, F. M. AU - Visseren, F. L. AU - Koning, E. J. AU - Rabelink, T. J. PY - 2005 DA - 2005// TI - Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes JO - J Cardiovasc Pharmacol VL - 46 UR - https://doi.org/10.1097/01.fjc.0000187176.13403.05 DO - 10.1097/01.fjc.0000187176.13403.05 ID - Martens2005 ER - TY - JOUR AU - Nissen, S. E. AU - Wolski, K. PY - 2007 DA - 2007// TI - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes JO - N Engl J Med VL - 356 UR - https://doi.org/10.1056/NEJMoa072761 DO - 10.1056/NEJMoa072761 ID - Nissen2007 ER - TY - STD TI - The Cochrane Public Health Group Guide for developing a Cochrane protocol. 2011. http://ph.cochrane.org/sites/ph.cochrane.org/files/public/uploads/Guide%20for%20PH%20protocol_Nov%202011_final%20for%20website.pdf. Accessed 3 May 2016. UR - http://ph.cochrane.org/sites/ph.cochrane.org/files/public/uploads/Guide%20for%20PH%20protocol_Nov%202011_final%20for%20website.pdf ID - ref24 ER - TY - STD TI - Quality of reporting of meta-analyses (QUORUM) checklist. 1–2. http://www.biomedcentral.com/content/supplementary/1471-2261-10-24-s1.pdf. Accessed 3 May 2016. UR - http://www.biomedcentral.com/content/supplementary/1471-2261-10-24-s1.pdf ID - ref25 ER - TY - STD TI - Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. http://www.ncbi.nlm.nih.gov/pubmed/22008217. Accessed 9 Jul 2016. UR - http://www.ncbi.nlm.nih.gov/pubmed/22008217 ID - ref26 ER - TY - STD TI - J.P. Higgins, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Tabel 8.5a: The Cochrane Collaboration’s tool for assessing risk of bias. http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm. Accessed 4 May 2016. UR - http://handbook.cochrane.org/chapter_8/table_8_5_a_the_cochrane_collaborations_tool_for_assessing.htm ID - ref27 ER - TY - STD TI - Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. 9.5.2 Identifying and measuring heterogeneity. http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm. Accessed 3 May 2016. UR - http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm ID - ref28 ER - TY - JOUR AU - Hong, S. J. AU - Choi, S. C. AU - Cho, J. Y. AU - Joo, H. J. AU - Park, J. H. AU - Yu, C. W. PY - 2015 DA - 2015// TI - Pioglitazone increases circulating microRNA-24 with decrease in coronary neointimal hyperplasia in type 2 diabetic patients- optical coherence tomography analysis JO - Circ J VL - 79 UR - https://doi.org/10.1253/circj.CJ-14-0964 DO - 10.1253/circj.CJ-14-0964 ID - Hong2015 ER - TY - JOUR AU - Lee, H. W. AU - Lee, H. C. AU - Kim, B. W. AU - Yang, M. J. AU - Park, J. S. AU - Oh, J. H. PY - 2013 DA - 2013// TI - Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation JO - Yonsei Med J VL - 54 UR - https://doi.org/10.3349/ymj.2013.54.6.1313 DO - 10.3349/ymj.2013.54.6.1313 ID - Lee2013 ER - TY - JOUR AU - Suryadevara, S. AU - Ueno, M. AU - Tello-Montoliu, A. AU - Ferreiro, J. L. AU - Desai, B. AU - Rollini, F. PY - 2012 DA - 2012// TI - Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus JO - Thromb Haemost VL - 108 UR - https://doi.org/10.1160/TH12-06-0397 DO - 10.1160/TH12-06-0397 ID - Suryadevara2012 ER - TY - JOUR AU - Takagi, T. AU - Okura, H. AU - Kobayashi, Y. AU - Kataoka, T. AU - Taguchi, H. AU - Toda, I. PY - 2009 DA - 2009// TI - A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (prevention of in-stent neointimal proliferation by pioglitazone study) JO - JACC Cardiovasc Interv. VL - 2 UR - https://doi.org/10.1016/j.jcin.2009.04.007 DO - 10.1016/j.jcin.2009.04.007 ID - Takagi2009 ER - TY - JOUR AU - Kaneda, H. AU - Shiono, T. AU - Miyashita, Y. AU - Takahashi, S. AU - Taketani, Y. AU - Domae, H. PY - 2009 DA - 2009// TI - Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation JO - Heart VL - 95 UR - https://doi.org/10.1136/hrt.2008.162842 DO - 10.1136/hrt.2008.162842 ID - Kaneda2009 ER - TY - JOUR AU - Nishio, K. AU - Sakurai, M. AU - Kusuyama, T. AU - Shigemitsu, M. AU - Fukui, T. AU - Kawamura, K. PY - 2006 DA - 2006// TI - A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes JO - Diabetes Care VL - 29 UR - https://doi.org/10.2337/diacare.29.01.06.dc05-1170 DO - 10.2337/diacare.29.01.06.dc05-1170 ID - Nishio2006 ER - TY - JOUR AU - Wilcox, R. AU - Bousser, M. G. AU - Betteridge, D. J. AU - Schernthaner, G. AU - Pirags, V. AU - Kupfer, S. PY - 2007 DA - 2007// TI - Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) JO - Stroke VL - 38 UR - https://doi.org/10.1161/01.STR.0000257974.06317.49 DO - 10.1161/01.STR.0000257974.06317.49 ID - Wilcox2007 ER - TY - JOUR AU - Wilcox, R. AU - Kupfer, S. AU - Erdmann, E. PY - 2008 DA - 2008// TI - Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) JO - Am Heart J VL - 155 UR - https://doi.org/10.1016/j.ahj.2007.11.029 DO - 10.1016/j.ahj.2007.11.029 ID - Wilcox2008 ER - TY - JOUR AU - Liu, J. AU - Wang, L. N. PY - 2015 DA - 2015// TI - Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack JO - Cochrane Database Syst Rev ID - Liu2015 ER - TY - JOUR AU - Liao, H. AU - Saver, J. L. AU - Wu, Y. AU - Chen, T. AU - Lee, M. AU - Ovbiagele, B. PY - 2017 DA - 2017// TI - Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis JO - BMJ VL - 7 ID - Liao2017 ER - TY - JOUR AU - Lee, M. AU - Saver, J. L. AU - Liao, H. W. AU - Lin, C. H. AU - Ovbiagele, B. PY - 2017 DA - 2017// TI - Pioglitazone for secondary stroke prevention JO - Stroke VL - 48 UR - https://doi.org/10.1161/STROKEAHA.116.013977 DO - 10.1161/STROKEAHA.116.013977 ID - Lee2017 ER - TY - JOUR AU - Varas-Lorenzo, C. AU - Margulis, A. V. AU - Pladevall, M. AU - Riera-Guardia, N. AU - Calingaert, B. AU - Hazell, L. PY - 2014 DA - 2014// TI - The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies JO - BMC Cardiovasc Disord. VL - 14 UR - https://doi.org/10.1186/1471-2261-14-129 DO - 10.1186/1471-2261-14-129 ID - Varas-Lorenzo2014 ER - TY - JOUR AU - Hernandez, A. V. AU - Usmani, A. AU - Rajamanickam, A. AU - Moheet, A. PY - 2011 DA - 2011// TI - Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus JO - Am J Cardiovasc Drugs. VL - 11 UR - https://doi.org/10.2165/11587580-000000000-00000 DO - 10.2165/11587580-000000000-00000 ID - Hernandez2011 ER - TY - JOUR AU - Lincoff, A. M. AU - Wolski, K. AU - Nicholls, S. J. AU - Nissen, S. E. PY - 2007 DA - 2007// TI - Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus JO - JAMA VL - 298 UR - https://doi.org/10.1001/jama.298.10.1180 DO - 10.1001/jama.298.10.1180 ID - Lincoff2007 ER - TY - JOUR AU - Nitta, Y. AU - Tahara, N. AU - Tahara, A. AU - Honda, A. AU - Kodama, N. AU - Mizoguchi, M. PY - 2013 DA - 2013// TI - Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging JO - JACC Cardiovasc Imaging. VL - 6 UR - https://doi.org/10.1016/j.jcmg.2013.09.004 DO - 10.1016/j.jcmg.2013.09.004 ID - Nitta2013 ER - TY - STD TI - Ogasawara D, Shite J, Shinke T, Watanabe S, Otake H, Tanino Y, et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J. 2009;73:343–51. http://www.ncbi.nlm.nih.gov/pubmed/19096190. UR - http://www.ncbi.nlm.nih.gov/pubmed/19096190 ID - ref44 ER - TY - JOUR AU - Christoph, M. AU - Herold, J. AU - Berg-Holldack, A. AU - Rauwolf, T. AU - Ziemssen, T. AU - Schmeisser, A. PY - 2015 DA - 2015// TI - Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial JO - Heart Vessels VL - 30 UR - https://doi.org/10.1007/s00380-014-0480-0 DO - 10.1007/s00380-014-0480-0 ID - Christoph2015 ER - TY - JOUR AU - Marx, N. AU - Wöhrle, J. AU - Nusser, T. AU - Walcher, D. AU - Rinker, A. AU - Hombach, V. PY - 2005 DA - 2005// TI - Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled JO - Double-Blind Trial in Nondiabetic Patients. Circulation. VL - 112 ID - Marx2005 ER - TY - JOUR AU - Nesto, R. W. AU - Bell, D. AU - Bonow, R. O. AU - Fonseca, V. AU - Grundy, S. M. AU - Horton, E. S. PY - 2004 DA - 2004// TI - Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association JO - Diabetes Care VL - 27 UR - https://doi.org/10.2337/diacare.27.1.256 DO - 10.2337/diacare.27.1.256 ID - Nesto2004 ER - TY - JOUR AU - Hughes, A. D. AU - Park, C. AU - March, K. AU - Coady, E. AU - Khir, A. AU - Chaturvedi, N. PY - 2013 DA - 2013// TI - A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes JO - Int J Cardiol VL - 167 UR - https://doi.org/10.1016/j.ijcard.2012.03.179 DO - 10.1016/j.ijcard.2012.03.179 ID - Hughes2013 ER - TY - JOUR AU - Ordu, S. AU - Ozhan, H. AU - Alemdar, R. AU - Aydin, M. AU - Basar, C. AU - Caglar, O. PY - 2010 DA - 2010// TI - Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study JO - Acta Cardiol VL - 65 ID - Ordu2010 ER - TY - JOUR AU - Terui, G. AU - Goto, T. AU - Katsuta, M. AU - Aoki, I. AU - Ito, H. PY - 2009 DA - 2009// TI - Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients JO - J Cardiol VL - 54 UR - https://doi.org/10.1016/j.jjcc.2009.03.004 DO - 10.1016/j.jjcc.2009.03.004 ID - Terui2009 ER - TY - JOUR AU - Oe, H. AU - Nakamura, K. AU - Kihara, H. AU - Shimada, K. AU - Fukuda, S. AU - Takagi, T. PY - 2015 DA - 2015// TI - Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial JO - Cardiovasc Diabetol. VL - 14 UR - https://doi.org/10.1186/s12933-015-0242-z DO - 10.1186/s12933-015-0242-z ID - Oe2015 ER - TY - STD TI - Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E, et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes care. 2017:dc170078. doi:10.2337/dc17-0078. ID - ref52 ER - TY - JOUR AU - Berlie, H. D. AU - Kalus, J. S. AU - Jaber, L. A. PY - 2007 DA - 2007// TI - Thiazolidinediones and the risk of edema: a meta-analysis JO - Diabetes Res Clin Pract VL - 76 UR - https://doi.org/10.1016/j.diabres.2006.09.010 DO - 10.1016/j.diabres.2006.09.010 ID - Berlie2007 ER - TY - JOUR AU - Lu, C. J. AU - Sun, Y. AU - Muo, C. H. AU - Chen, R. C. AU - Chen, P. C. AU - Hsu, C. Y. PY - 2013 DA - 2013// TI - Risk of stroke with thiazolidinediones: a 10-year nationwide population-based cohort study JO - Cerebrovasc Dis. VL - 36 UR - https://doi.org/10.1159/000353679 DO - 10.1159/000353679 ID - Lu2013 ER - TY - JOUR AU - Lewis, J. D. AU - Habel, L. A. AU - Quesenberry, C. P. AU - Strom, B. L. AU - Peng, T. AU - Hedderson, M. M. PY - 2015 DA - 2015// TI - Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes JO - JAMA VL - 314 UR - https://doi.org/10.1001/jama.2015.7996 DO - 10.1001/jama.2015.7996 ID - Lewis2015 ER - TY - JOUR AU - Erdmann, E. AU - Charbonnel, B. AU - Wilcox, R. G. AU - Skene, A. M. AU - Massi-Benedetti, M. AU - Yates, J. PY - 2007 DA - 2007// TI - Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08) JO - Diabetes Care VL - 30 UR - https://doi.org/10.2337/dc07-0717 DO - 10.2337/dc07-0717 ID - Erdmann2007 ER - TY - JOUR AU - Tuccori, M. AU - Filion, K. B. AU - Yin, H. AU - Yu, O. H. AU - Platt, R. W. AU - Azoulay, L. PY - 2016 DA - 2016// TI - Pioglitazone use and risk of bladder cancer: population based cohort study JO - BMJ VL - 352 UR - https://doi.org/10.1136/bmj.i1541 DO - 10.1136/bmj.i1541 ID - Tuccori2016 ER - TY - JOUR AU - Zhu, Z. N. AU - Jiang, Y. F. AU - Ding, T. PY - 2014 DA - 2014// TI - Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials JO - Bone VL - 68 UR - https://doi.org/10.1016/j.bone.2014.08.010 DO - 10.1016/j.bone.2014.08.010 ID - Zhu2014 ER - TY - JOUR AU - Levin, D. AU - Bell, S. AU - Sund, R. AU - Hartikainen, S. A. AU - Tuomilehto, J. AU - Pukkala, E. PY - 2015 DA - 2015// TI - Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis JO - Diabetologia VL - 58 UR - https://doi.org/10.1007/s00125-014-3456-9 DO - 10.1007/s00125-014-3456-9 ID - Levin2015 ER - TY - JOUR AU - Erdmann, E. AU - Song, E. AU - Spanheimer, R. AU - Troostenburg de Bruyn, A. -. R. AU - Perez, A. PY - 2014 DA - 2014// TI - Observational follow-up of the PROactive study: a 6-year update JO - Diabetes Obes Metab VL - 16 UR - https://doi.org/10.1111/dom.12180 DO - 10.1111/dom.12180 ID - Erdmann2014 ER - TY - STD TI - Highlights of prescribing information. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf. Accessed 15 Sep 2017. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf ID - ref61 ER - TY - STD TI - American Diabetes Association. Diabetes care. American Diabetes Association. 2017;40(1). http://care.diabetesjournals.org/content/40/Supplement_1. Accessed 29 Sep 2017. UR - http://care.diabetesjournals.org/content/40/Supplement_1 ID - ref62 ER - TY - JOUR AU - Ou, H. T. AU - Chang, K. C. AU - Li, C. Y. AU - Wu, J. S. PY - 2016 DA - 2016// TI - Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study JO - Cardiovasc Diabetol. VL - 15 UR - https://doi.org/10.1186/s12933-016-0350-4 DO - 10.1186/s12933-016-0350-4 ID - Ou2016 ER -